封面
市場調查報告書
商品編碼
1718160

雙特異性抗體市場(按作用機制、治療領域和最終用戶分類)—2025-2030 年全球預測

Bispecific Antibodies Market by Mechanism of Action, Therapeutic Area, End-user - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年雙特異性抗體市值為 57.1 億美元,預計 2024 年將成長至 74.9 億美元,複合年成長率為 32.64%,預計到 2030 年將達到 412.9 億美元。

主要市場統計數據
基準年2023年 57.1億美元
預計2024年 74.9億美元
預測年份 2030 412.9億美元
複合年成長率(%) 32.64%

雙特異性抗體正迅速成為突破性治療方法,重新定義多個疾病領域的治療範例。在當今精準和有針對性的干涉至關重要的環境下,這種創新藥物處於生物醫學的前沿。設計同時針對兩種不同抗原的抗體的科學已取得重大進展,比傳統治療方法具有更高的特異性和有效性。本報告對雙特異性抗體市場進行了深入分析,探討了市場促進因素、技術突破和不斷發展的市場策略。透過檢驗臨床進展和潛在的分子機制,我們將雙特異性抗體的治療潛力置於現代醫學的更廣泛背景中。它面向尋求了解這一動態領域的影響和未來發展軌蹟的行業專業人士和關鍵決策者,重點關注影響決策的策略和管理方面。這篇綜合評論表明,雙特異性抗體在重塑各種治療應用的治療策略方面具有巨大的價值,並且在市場上發展勢頭強勁。

改變雙特異性抗體市場

雙特異性抗體市場正在經歷變革時期,其驅動力是重塑臨床和商業策略的關鍵進展。技術進步加速了這些複雜分子的發現和最佳化,最終透過複雜的分子工程實現了與目標抗原的增強結合。監管方法也在不斷發展,在快速上市途徑和嚴格的安全評估之間取得平衡,以保持高標準。製藥公司和生物技術創新者之間的策略聯盟進一步推動了這種轉變,形成了一個競爭而又共生的生態系統,加速了臨床試驗以及從實驗室到臨床的轉變。對自適應臨床設計和強巨量資料分析的投資揭示了重要的功效和安全性,使公司能夠改善患者選擇並最大限度地提高治療效果。這種不斷發展的格局的特點是科學發現、不斷發展的監管格局和市場適應之間的動態相互作用,凸顯了相關人員在快速變化的環境中保持知情並採取靈活行動的必要性。透過利用這些變革性轉變,產業領導者可以充分利用雙特異性抗體的潛力來推動有意義的臨床進展。

關鍵細分洞察

詳細的細分分析可以更深入地了解雙特異性抗體市場,闡明有針對性的干涉途徑,並揭示成長機會。基於機制的市場研究表明,雙抗原靶向、雙阻斷抗體和 T 細胞接合劑等方法在塑造治療結果和市場動態方面發揮關鍵作用。同時,基於治療領域的細分顯示,從自體免疫疾病和感染疾病到神經系統疾病和腫瘤等多種疾病都是臨床應用的關鍵促進因素。這種多方面的方法使相關人員能夠精確定位未滿足需求最大的領域,以及與新興臨床證據最相符的潛在收益來源。此外,透過區分醫院和專科診所的應用以及研究機構和學術中心的應用,最終用戶細分可以更清楚地了解市場。這些相互關聯的觀點不僅完善了市場目標,而且還有助於更深入地了解以患者為中心的需求、臨床需求以及治療方法的整體演變。對於尋求建立有彈性的投資組合和實施有效的打入市場策略的策略家來說,認知這些細分變數至關重要。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球感染疾病和慢性病發生率上升
      • 基因和蛋白質工程的進展
      • 擴大對新型雙特異性抗體開發和核准的監管支持
    • 限制因素
      • 雙特異性抗體製造的複雜性
    • 機會
      • 個人化治療方法的新興趨勢
      • 擴大雙特異性抗體在治療罕見疾病的應用
    • 任務
      • 雙特異性抗體的安全性和有效性問題
  • 市場區隔分析
    • 作用機轉:提高雙抗原標標靶化的優先級,以最大限度地減少脫靶效應
    • 治療領域:擴大雙特異性抗體在腫瘤學中的應用,以捕捉和摧毀癌細胞
    • 最終使用者:在醫院和專科診所提供全面的治療護理
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 雙特異性抗體市場(依作用機轉)

  • 雙抗原標靶
  • 雙重阻斷抗體
  • T細胞銜接子

第7章雙特異性抗體市場(依治療領域)

  • 自體免疫疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學

第8章雙特異性抗體市場(依最終用戶)

  • 醫院和專科診所
  • 研究機構和學術中心

9. 美洲雙特異性抗體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

10. 亞太地區雙特異性抗體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

11. 歐洲、中東和非洲雙特異性抗體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • Adimab, LLC
  • Affimed GmbH
  • Alligator Bioscience AB
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mereo Biopharma Group PLC
  • Merus NV
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • TG Therapeutics, Inc.
  • Xencor, Inc.
Product Code: MRR-F97DD5A7DF65

The Bispecific Antibodies Market was valued at USD 5.71 billion in 2023 and is projected to grow to USD 7.49 billion in 2024, with a CAGR of 32.64%, reaching USD 41.29 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 5.71 billion
Estimated Year [2024] USD 7.49 billion
Forecast Year [2030] USD 41.29 billion
CAGR (%) 32.64%

Bispecific antibodies are rapidly emerging as groundbreaking therapeutic modalities, redefining treatment paradigms across multiple disease areas. In today's environment, where precision and targeted intervention are paramount, these innovative agents stand at the forefront of biomedical science. The science behind designing antibodies that can engage two different antigens simultaneously has advanced considerably, providing superior specificity and potency compared to traditional therapies. This report offers an in-depth analysis of the bispecific antibody market, exploring critical drivers, technological breakthroughs, and evolving market strategies. By examining both clinical advancements and underlying molecular mechanisms, the narrative places the therapeutic potential of bispecific antibodies in a broader context of modern medicine. With a focus on the strategic and operational aspects that influence decision-making, the discussion is tailored for industry experts and key decision-makers looking to understand the impact and future trajectory of this dynamic segment. This comprehensive exploration underscores the immense value and growing market influence of bispecific antibodies in reshaping treatment landscapes across a diverse array of therapeutic applications.

Transformative Shifts in the Landscape

The bispecific antibodies market is undergoing a transformative shift driven by significant advancements that are reshaping both clinical and commercial strategies. Technological innovations have accelerated the discovery and optimization of these complex molecules, ultimately allowing for enhanced engagement with target antigens through refined molecular engineering. Regulatory agencies have also evolved in their approach, balancing expedited pathways to market with stringent safety evaluations to maintain high standards. These shifts are further bolstered by strategic collaborations between pharmaceutical companies and biotechnology innovators, fostering a competitive yet symbiotic ecosystem that accelerates clinical trials and bench-to-bedside transitions. Investment in adaptive clinical design and robust data analytics has illuminated critical efficacy and safety profiles, making it possible for companies to refine patient selection and maximize therapeutic outcomes. This evolving landscape is characterized by the dynamic interplay between scientific discovery, regulatory progression, and market adaptation, underscoring the necessity for stakeholders to remain informed and agile in a rapidly changing environment. By leveraging these transformative shifts, industry leaders are uniquely positioned to harness the full potential of bispecific antibodies and drive meaningful clinical advancements.

Key Segmentation Insights

A detailed segmentation analysis provides a nuanced understanding of the bispecific antibodies market, clarifying avenues for targeted intervention and highlighting growth opportunities. When studying the market based on the mechanism of action, it becomes clear that approaches such as dual antigen targeting, dual-blocking antibodies, and T-cell engagers play pivotal roles in shaping therapeutic efficacy and market dynamics. In parallel, segmentation based on therapeutic area reveals that conditions ranging from autoimmune diseases and infectious diseases to neurological disorders and oncology form the cornerstone of clinical application. This multifaceted approach allows stakeholders to pinpoint segments where unmet needs are highest and potential revenue streams are optimally aligned with emerging clinical evidence. Furthermore, the end-user segmentation delineates the market landscape by distinguishing applications within hospitals and specialist clinics from those pursued in research institutions and academic centers. These interconnected perspectives not only refine market targeting but also foster a deeper understanding of patient-centric needs, clinical demands, and the overall evolution of treatment methodologies. Recognizing these segmentation variables is essential for strategists looking to create a resilient portfolio and implement effective market entry strategies.

Based on Mechanism of Action, market is studied across Dual Antigen Targeting, Dual-Blocking Antibodies, and T-cell Engagers.

Based on Therapeutic Area, market is studied across Autoimmune Diseases, Infectious Diseases, Neurological Disorders, and Oncology.

Based on End-user, market is studied across Hospitals & Specialist Clinics and Research Institutions & Academic Centers.

Key Regional Insights

Geographic dynamics play a crucial role in determining market trends and resource allocation in the bispecific antibodies domain. In-depth analysis across various regions reveals distinctive characteristics that influence both product development and adoption rates. The Americas showcase robust infrastructure with thriving biopharmaceutical networks and advanced clinical research facilities that have propelled rapid commercialization. Meanwhile, regions such as Europe, the Middle East, and Africa are witnessing steady growth, supported by comprehensive regulatory reforms and strategic public-private partnerships fostering increased investment in innovative therapies. The Asia-Pacific region, with its burgeoning markets and escalating levels of healthcare expenditure, represents a frontier of potential, driving a surge in clinical research initiatives and collaborative ventures. The integration of region-specific insights with overarching market analysis underscores the importance of tailoring strategies to local nuances while leveraging global industry trends. These regional differentiators not only create diverse investment opportunities but also encourage harmonized regulatory landscapes and drive the broader acceptance of bispecific antibody technologies across varied demographic and economic settings.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, Michigan, Montana, New York, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

The bispecific antibodies market is characterized by the active participation of a range of influential companies, each contributing unique technological capabilities and strategic direction. Industry leaders such as AbbVie Inc., Adimab, LLC, and Affimed GmbH continue to drive innovation through focused research and robust clinical development programs. Companies like Alligator Bioscience AB and Amgen Inc. have advanced their portfolios by capitalizing on novel therapeutic modalities to address unmet medical needs. Other major players, including Astellas Pharma Inc. and AstraZeneca PLC, have integrated bispecific approaches into comprehensive treatment strategies, further complemented by the expertise of Bristol-Myers Squibb and Eli Lilly and Company. Notable contributions from Emergent BioSolutions Inc. and F. Hoffmann-La Roche Ltd. have provided clarity in regulatory pathways and clinical trial design, while Genmab A/S and Gilead Sciences, Inc. have leveraged synergistic partnerships to accelerate drug development. Innovent Biologics, Inc., Johnson & Johnson Services, Inc., and Merck KGaA continue to shape the competitive landscape with robust research pipelines. Other recognized companies such as Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc. bring valuable insights and diversified strategies, collectively reinforcing the market's innovation ecosystem.

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Alligator Bioscience AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are urged to harness the transformative trends within the bispecific antibodies market by integrating strategic, research-driven, and patient-focused approaches into their core business models. A comprehensive review of existing portfolios is critical, with companies encouraged to invest in state-of-the-art technologies that facilitate rapid candidate screening and reliable efficacy assessments. Capitalizing on cross-disciplinary partnerships can expedite the translation of novel research findings into clinical applications, thereby bridging the gap between innovation and market readiness. Leaders should also pay careful attention to evolving regulatory frameworks and invest in building agile compliance systems that enable swift adjustments to new guidelines. It is imperative to align R&D strategies with insights derived from detailed segmentation analyses, ensuring that therapeutic development is both targeted and adaptive. Dedicated initiatives to nurture talent in emerging fields, coupled with an emphasis on robust clinical trial designs, can further strengthen a company's market positioning. By adopting these actionable recommendations, decision-makers can not only mitigate risks but also drive sustainable growth, fortifying their competitive edge in a rapidly advancing therapeutic landscape.

Conclusion: Charting the Future of Bispecific Antibodies

In summary, the bispecific antibodies market is at a pivotal juncture, where rapid technological advances meet unmet clinical needs. The extensive segmentation analysis, coupled with evolving regional trends and significant contributions from leading companies, paints a comprehensive picture of a dynamic and promising therapeutic landscape. With transformative shifts in market paradigms and a clear delineation of strategic opportunities, stakeholders are well-positioned to propel innovation and optimize patient outcomes. The interplay between science, regulatory action, and market dynamics creates a fertile ground for sustained growth and renewed confidence from investors and clinicians alike. As companies fine-tune their strategies to harness these emerging opportunities, the future of bispecific antibodies looks set to redefine conventional treatment methodologies and offer unprecedented clinical benefits. This conclusion not only celebrates current achievements but also serves as a clarion call for further research, investment, and strategic alignment in this fast-evolving market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of infectious and chronic illnesses globally
      • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
      • 5.1.1.3. Growing regulatory support for the development and approval of novel bispecific antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the manufacturing of bispecific antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend toward personalized therapeutic approaches
      • 5.1.3.2. Expanding usage of bispecific antibodies in the treatment of rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with the safety and efficacy of bispecific antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
    • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
    • 5.2.3. End-user: Provision of comprehensive therapeutic care in hospitals and specialist clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bispecific Antibodies Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. Dual Antigen Targeting
  • 6.3. Dual-Blocking Antibodies
  • 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Infectious Diseases
  • 7.4. Neurological Disorders
  • 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals & Specialist Clinics
  • 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Merck & Co Inc expands oncology portfolio with acquisition of novel bispecific antibody for B-cell malignancies
    • 12.3.2. Novartis collaborates with Dren Bio, for innovative bispecific antibodies to revolutionize cancer treatments
    • 12.3.3. Johnson & Johnson's Acquisition of Numab Therapeutics Boosting Bispecific Antibody Pipeline
    • 12.3.4. Regeneron highlights promising anti-tumor activity of novel bispecific antibody REGN7075
    • 12.3.5. Zenas Biopharma raises USD 200 Million in Series C Funding
    • 12.3.6. Invenra and Astellas Pharma form strategic partnership to enhance bispecific antibody R&D using the B-Body platform
    • 12.3.7. Biotheus and Hansoh Pharma expand partnership to develop innovative bispecific antibody-drug conjugates for cancer treatment
    • 12.3.8. FDA approves Johnson & Johnson's TECVAYLI for biweekly dosing in multiple myeloma
    • 12.3.9. AstraZeneca advances cancer treatment with innovative bispecific antibodies targeting multiple tumor antigens
    • 12.3.10. Janssen's TALVEY talquetamab-tgvs receives FDA accelerated approval
    • 12.3.11. FDA greenlights AbbVie and Genmab's EPKINLY for relapsed or refractory DLBCL
    • 12.3.12. Pfizer's elranatamab receives priority review by US FDA and EMA with positive trial results
  • 12.4. Strategy Analysis & Recommendation
    • 12.4.1. AbbVie Inc.
    • 12.4.2. AstraZeneca PLC
    • 12.4.3. F. Hoffmann-La Roche Ltd.
    • 12.4.4. Amgen Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adimab, LLC
  • 3. Affimed GmbH
  • 4. Alligator Bioscience AB
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bristol-Myers Squibb
  • 9. Eli Lilly and Company
  • 10. Emergent BioSolutions Inc.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Genmab A/S
  • 13. Gilead Sciences, Inc.
  • 14. Innovent Biologics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Mereo Biopharma Group PLC
  • 18. Merus N.V.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Pieris Pharmaceuticals, Inc.
  • 22. Regeneron Pharmaceuticals Inc.
  • 23. Sanofi S.A.
  • 24. TG Therapeutics, Inc.
  • 25. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. BISPECIFIC ANTIBODIES MARKET MULTI-CURRENCY
  • FIGURE 2. BISPECIFIC ANTIBODIES MARKET MULTI-LANGUAGE
  • FIGURE 3. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 4. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023